The effect of ε‐aminocaproic acid on blood product requirement, outcome and thromboelastography parameters in severely thrombocytopenic dogs

Abstract Background No treatment other than platelet administration is known to protect against spontaneous hemorrhage in thrombocytopenic dogs. Objectives Primary: determine if treatment with ε‐aminocaproic acid (EACA) decreases the requirement for blood transfusions and improves outcome in dogs wi...

Full description

Bibliographic Details
Main Authors: Johanna Wolf, Laura K. Ruterbories, Ian Handel, Bernie Hansen
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:Journal of Veterinary Internal Medicine
Subjects:
Online Access:https://doi.org/10.1111/jvim.16977
_version_ 1797263088247898112
author Johanna Wolf
Laura K. Ruterbories
Ian Handel
Bernie Hansen
author_facet Johanna Wolf
Laura K. Ruterbories
Ian Handel
Bernie Hansen
author_sort Johanna Wolf
collection DOAJ
description Abstract Background No treatment other than platelet administration is known to protect against spontaneous hemorrhage in thrombocytopenic dogs. Objectives Primary: determine if treatment with ε‐aminocaproic acid (EACA) decreases the requirement for blood transfusions and improves outcome in dogs with severe thrombocytopenia. Secondary: find evidence of hyperfibrinolysis and determine the effect EACA administration on rapid (rTEG) and tissue plasminogen activator‐spiked (tPA‐rTEG) thromboelastography parameters. Animals Twenty‐seven dogs with severe thrombocytopenia were treated with EACA, and data from an additional 33 were obtained from the hospital database as historical control (HC) cohort. Methods Single arm clinical trial with HCs. The EACA group dogs received EACA (100 mg/kg IV followed by a constant‐rate infusion [CRI] of 400 mg/kg/24 hours). Thromboelastography before and during EACA infusion, hospitalization days, number of transfusions, and mortality were compared. Results No difference was found in number of transfusions per dog (median, interquartile range; 1, 0‐2.5 vs 0.9, 0‐2; P = .5) and hospitalization days (4, 4‐6 vs 4.5, 3.75‐6; P = .83) between HC and EACA groups, respectively, and no difference in survival was identified by log‐rank analysis (P = .15). Maximum amplitude on both rTEG and tPA‐rTEG increased after EACA administration (rTEG baseline: 23.6, 9.6‐38.9; post‐EACA: 27.3, 19.8‐43.2; P < .001; tPA‐rTEG baseline: 23, 10.9‐37.2; post‐EACA: 24.7, 16.7‐44.8; P < .002). Conclusions and Clinical Importance Although EACA increased clot strength, there was no effect on outcome. Treatment with EACA at this dosage cannot be recommended as a routine treatment but may be considered for dogs with severe ongoing hemorrhage.
first_indexed 2024-04-25T00:07:27Z
format Article
id doaj.art-d484e5255afa4d0e986ce9e19e384e41
institution Directory Open Access Journal
issn 0891-6640
1939-1676
language English
last_indexed 2024-04-25T00:07:27Z
publishDate 2024-03-01
publisher Wiley
record_format Article
series Journal of Veterinary Internal Medicine
spelling doaj.art-d484e5255afa4d0e986ce9e19e384e412024-03-14T04:25:21ZengWileyJournal of Veterinary Internal Medicine0891-66401939-16762024-03-013821013102110.1111/jvim.16977The effect of ε‐aminocaproic acid on blood product requirement, outcome and thromboelastography parameters in severely thrombocytopenic dogsJohanna Wolf0Laura K. Ruterbories1Ian Handel2Bernie Hansen3Royal (Dick) School of Veterinary Studies University of Edinburgh, Easter Bush Campus Midlothian UKDepartment of Clinical Sciences, College of Veterinary Medicine North Carolina State University Raleigh North Carolina USARoyal (Dick) School of Veterinary Studies University of Edinburgh, Easter Bush Campus Midlothian UKDepartment of Clinical Sciences, College of Veterinary Medicine North Carolina State University Raleigh North Carolina USAAbstract Background No treatment other than platelet administration is known to protect against spontaneous hemorrhage in thrombocytopenic dogs. Objectives Primary: determine if treatment with ε‐aminocaproic acid (EACA) decreases the requirement for blood transfusions and improves outcome in dogs with severe thrombocytopenia. Secondary: find evidence of hyperfibrinolysis and determine the effect EACA administration on rapid (rTEG) and tissue plasminogen activator‐spiked (tPA‐rTEG) thromboelastography parameters. Animals Twenty‐seven dogs with severe thrombocytopenia were treated with EACA, and data from an additional 33 were obtained from the hospital database as historical control (HC) cohort. Methods Single arm clinical trial with HCs. The EACA group dogs received EACA (100 mg/kg IV followed by a constant‐rate infusion [CRI] of 400 mg/kg/24 hours). Thromboelastography before and during EACA infusion, hospitalization days, number of transfusions, and mortality were compared. Results No difference was found in number of transfusions per dog (median, interquartile range; 1, 0‐2.5 vs 0.9, 0‐2; P = .5) and hospitalization days (4, 4‐6 vs 4.5, 3.75‐6; P = .83) between HC and EACA groups, respectively, and no difference in survival was identified by log‐rank analysis (P = .15). Maximum amplitude on both rTEG and tPA‐rTEG increased after EACA administration (rTEG baseline: 23.6, 9.6‐38.9; post‐EACA: 27.3, 19.8‐43.2; P < .001; tPA‐rTEG baseline: 23, 10.9‐37.2; post‐EACA: 24.7, 16.7‐44.8; P < .002). Conclusions and Clinical Importance Although EACA increased clot strength, there was no effect on outcome. Treatment with EACA at this dosage cannot be recommended as a routine treatment but may be considered for dogs with severe ongoing hemorrhage.https://doi.org/10.1111/jvim.16977antifibrinolyticshyperfibrinolysisplateletsthrombocytopenia
spellingShingle Johanna Wolf
Laura K. Ruterbories
Ian Handel
Bernie Hansen
The effect of ε‐aminocaproic acid on blood product requirement, outcome and thromboelastography parameters in severely thrombocytopenic dogs
Journal of Veterinary Internal Medicine
antifibrinolytics
hyperfibrinolysis
platelets
thrombocytopenia
title The effect of ε‐aminocaproic acid on blood product requirement, outcome and thromboelastography parameters in severely thrombocytopenic dogs
title_full The effect of ε‐aminocaproic acid on blood product requirement, outcome and thromboelastography parameters in severely thrombocytopenic dogs
title_fullStr The effect of ε‐aminocaproic acid on blood product requirement, outcome and thromboelastography parameters in severely thrombocytopenic dogs
title_full_unstemmed The effect of ε‐aminocaproic acid on blood product requirement, outcome and thromboelastography parameters in severely thrombocytopenic dogs
title_short The effect of ε‐aminocaproic acid on blood product requirement, outcome and thromboelastography parameters in severely thrombocytopenic dogs
title_sort effect of ε aminocaproic acid on blood product requirement outcome and thromboelastography parameters in severely thrombocytopenic dogs
topic antifibrinolytics
hyperfibrinolysis
platelets
thrombocytopenia
url https://doi.org/10.1111/jvim.16977
work_keys_str_mv AT johannawolf theeffectofeaminocaproicacidonbloodproductrequirementoutcomeandthromboelastographyparametersinseverelythrombocytopenicdogs
AT laurakruterbories theeffectofeaminocaproicacidonbloodproductrequirementoutcomeandthromboelastographyparametersinseverelythrombocytopenicdogs
AT ianhandel theeffectofeaminocaproicacidonbloodproductrequirementoutcomeandthromboelastographyparametersinseverelythrombocytopenicdogs
AT berniehansen theeffectofeaminocaproicacidonbloodproductrequirementoutcomeandthromboelastographyparametersinseverelythrombocytopenicdogs
AT johannawolf effectofeaminocaproicacidonbloodproductrequirementoutcomeandthromboelastographyparametersinseverelythrombocytopenicdogs
AT laurakruterbories effectofeaminocaproicacidonbloodproductrequirementoutcomeandthromboelastographyparametersinseverelythrombocytopenicdogs
AT ianhandel effectofeaminocaproicacidonbloodproductrequirementoutcomeandthromboelastographyparametersinseverelythrombocytopenicdogs
AT berniehansen effectofeaminocaproicacidonbloodproductrequirementoutcomeandthromboelastographyparametersinseverelythrombocytopenicdogs